Ki-67 Labeling Index Based on Clinicopathological Characteristics in Triple Negative Breast Carcinoma (TNBC)

Abstract

Nowadays, breast cancer has been known as heterogenous disease with various biological features which require different therapy strategies. Breast cancers with lack or no expression of estrogen (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER-2) are defined as triple negative breast cancer (TNBC). To date, Ki-67 has been used in order to characterize cell proliferation. This study is to analyze Ki-67 labeling index (LI) expression based on clinicopathological features of TNBC. This descriptive study with cross-sectional design was performed. Data about demographics were extracted from patients' medical record and histopathologic feature and immunohistochemistry was done. Results of analysis data were presented in frequency tables. Mean and standard deviation Ki-67 LI were also obtained. In this study, most patients aged 35-49 years old with mean of 46,8 years old. Most of them had bigger tumour size, had already metastasized to lymph node, had no distant metastases and higher stage. Ki-67 LI value in this study quite high with mean of 43,89%. %. If TNBC patients were young, had distant metastases, higher mitotic count (≥15/10 HPF) and higher grade, they tended to have higher Ki-67 LI. Patients with metaplastic carcinoma of no special type and carcinoma with medullary features also tended to have higher Ki-67 LI. Meanwhile tumour size, metastases to lymph node and clinical stage were not in accordance with Ki-67 LI.